Objective:
To present interim safety and efficacy results of laru-zova in patients with X-linked retinitis pigmentosa (XLRP).
Key Findings:
- Laru-zova was generally well-tolerated by participants evaluated at 6 months or beyond.
- Promising improvements in visual function were observed across several key measures.
Interpretation:
The initial data suggest that laru-zova may be a promising treatment option for patients with XLRP, particularly those previously treated with AAV vector-based gene therapy.
Limitations:
- The study is open-label, which may introduce bias.
- Results are based on interim data and require further validation in larger trials.
Conclusion:
The DAWN trial indicates potential efficacy and safety of laru-zova, supporting its continued development in the pivotal phase 2/3 VISTA trial.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.